EcoR1 Capital’s Quince Therapeutics QNCX Stock Holding History

EcoR1 Capital’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-250	Closed	-$1.25M	–	51
2019 Q3	$1.25M	Buy	+250	New	+$1.54M	0.16%	34

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SUT

SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EcoR1 Capital's QNCX Position: Q4 2019 in Review

EcoR1 Capital sold out of Quince Therapeutics (QNCX) in Q4 2019, closing a stake of 250 shares — an estimated $1.25M sold.

EcoR1 Capital first reported a position in QNCX in Q3 2019 and held it in 1 quarter. The position peaked at $1.25M in Q3 2019. 50 funds tracked by Wall St. Rank hold QNCX as of Q4 2019.

EcoR1 Capital reported no remaining Quince Therapeutics position as of Q4 2019 after selling out during the quarter.
EcoR1 Capital sold 250 Quince Therapeutics shares in Q4 2019, an estimated $1.25M.
EcoR1 Capital first reported a position in Quince Therapeutics in Q3 2019 and held it in 1 quarter.
EcoR1 Capital's Quince Therapeutics position peaked at $1.25M in Q3 2019.
50 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2019.

Based on EcoR1 Capital's 13F filing for Q4 2019, filed 14 Feb 2020.